Opvee (Nalmefene) Will Be Released in the Fourth Quarter of 2023

 Opvee (Nalmefene) Will Be Released in the Fourth Quarter of 2023

Opvee is indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in patients 12 years and older, as manifested by respiratory and/or central nervous system depression. Opvee is the first FDA approval of nalmefene hydrochloride for use as a nasal spray. Nalmefene is currently available in an injectable formulation for opioid overdose. Opvee’s anticipated release is in the fourth quarter of 2023 and it will require a prescription.

If you have any questions or if we may assist you with your workers’ compensation pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.